What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|
Company | Oct. 21 | Weekly Gain | My Watchlist |
|---|---|---|---|
| Halozyme Therapeutics (Nasdaq: HALO) | $8.22 | 35% | Add |
| Select Comfort (Nasdaq: SCSS) | $21.57 | 33% | Add |
| Seagate (Nasdaq: STX) | $15.42 | 31% | Add |
| Brigham Exploration (Nasdaq: BEXP) | $36.54 | 20% | Add |
| Human Genome Sciences (Nasdaq: HGSI) | $13.37 | 20% | Add |
Source: Barron's.
Halozyme surged after receiving positive results for its promising breast cancer drug. Herceptin is in the critical third and final phase of clinical trials.
Select Comfort investors are sleeping soundly after the Sleep Number bed maker posted better-than-expected third-quarter results and juiced up its outlook for the entire year. Big-ticket mattresses wouldn't seem like a booming business in this iffy climate, but consumers seem to be taking to Select Comfort's firmness-adjustable beds.
Seagate shares rose opportunistically last week. Thailand flooding has dealt a bigger blow to rival Western Digital's (NYSE: WDC) operations than to its own production there, giving Seagate a chance to gain market share.
Brigham popped after Norway's oil giant Statoil (NYSE: STO) revealed that it would buy the company in a $4.4 billion deal. Brigham closed just ahead of the $36.50 a share all-cash offer, suggesting the expectations of higher bids before this wedding is done.
Human Genome Sciences surged on buyout speculation, but we'll get a better read on the situation tomorrow when the company reports its quarterly results.
It was a great week for these five stocks. Now let's see if they're up for an encore.
Which of these five stocks do you think will continue to move higher? Share your thoughts in the comments box below.
